Oncotarget

Reviews:

Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology

Xiaofei Wang, Wenli Cheng, Chongqing Liu and Jingdong Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:40792-40799. https://doi.org/10.18632/oncotarget.8215

Metrics: PDF 1094 views  |   HTML 1220 views  |   ?  


Abstract

Xiaofei Wang1,*, Wenli Cheng2,*, Chongqing Liu1 and Jingdong Li1

1 Department of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

2 Department of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

* These authors have contributed equally to this work

Correspondence to:

Jingdong Li, email:

Keywords: thyroid cancer; papillary carcinoma; tall cell; molecular biology; review

Received: November 23, 2015 Accepted: March 01, 2016 Published: March 20, 2016

Abstract

Tall cell variant (TCV) of papillary thyroid carcinoma (PTC) has been recognized for the past few decades as an entity showing aggressive biological behavior; however, there is considerable controversy regarding the definition, clinical and pathological features of TCV because of its rarity and difficult diagnosis. No clinical features can accurately diagnose TCV. Thus, the results of histocytology, immunohistochemistry and molecular genetics tests have important clinical implications for diagnosis. Given the aggressiveness and the increased recurrence and poor survival rates, more aggressive treatment approach and rigorous follow-up is required for patients with TCV. In the present article, we undertook a comprehensive review to summarize and discuss the various aspects of this variant, from morphology to immunohistochemistry, and molecular abnormalities from a practical and daily practice-oriented point of view.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8215